Pancreatitis: The life-threatening reaction linked to weight loss injections
The medicines regulator is investigating after hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs.
The Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England have launched the Yellow Card Biobank project to examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by people's genetic makeup.
New MHRA data shows that since the drugs were licensed, there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have also been fatal.
The cases reported include:
181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro.
116 reported reactions of this kind linked to liraglutide.
113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy.
101 reported reactions of this kind linked to exenatide.
52 reported reactions of this sort linked to dulaglutide and 11 reported reactions to lixisenatide.
The fatalities reported include:
Five people died following acute and chronic pancreatitis linked to tirzepatide.
One person died following reported reactions of this kind linked to liraglutide.
One person died following reported reactions of this kind linked to semaglutide.
Three people died following reported reactions of this kind linked to exenatide.
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be.
Acute pancreatitis is a condition where the pancreas - a small organ behind the stomach that helps with digestion - becomes inflamed over a short period of time.
While it typically resolves within about a week, some people with severe acute pancreatitis can go on to develop serious complications.
The NHS says the most common symptoms of acute pancreatitis include sudden, severe abdominal pain, feeling or being sick and a fever or high temperature of 38C or more.
Chronic pancreatitis, on the other hand, is when the organ becomes permanently damaged from inflammation, and typically occurs after one or more attacks of acute pancreatitis.
The most common symptom of chronic pancreatitis is repeated episodes of severe abdominal pain, particularly in the middle or left side, which can move along your back. It is described as a burning or shooting pain that comes and goes. However, as the condition progresses, the painful episodes may become more frequent and severe.
Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with diabetes and ongoing nausea and vomiting.
The MHRA is calling for people who are taking GLP-1 medicine and have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme.
GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs.
The most common side effects, which may affect more than 1 in 10 patients, are gastrointestinal, including nausea, vomiting, constipation and diarrhoea, according to the MHRA. These are more likely to occur at the start of treatment or after a recent increase in dose.
While manageable, they can sometimes lead to more serious complications such as severe dehydration and kidney damage.
In 2024, the MHRA warned of other serious but less common side effects of GLP-1RAs, including pancreatitis and gall bladder disorders, which may occur in between 1 in 100 and 1 in 10,000 patients.
Hypoglycemia, or low blood sugar, can also occur in non-diabetic patients using some GLP-1RAs for weight management.
Professor Matt Brown, chief scientific officer of Genomics England, said that like all medicines, 'there can be a risk of serious side effects'.
'We believe there is real potential to minimise these, with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Supermarkets to introduce healthy food standard under government plans to tackle obesity
A healthy food standard will be introduced for supermarkets and other retailers as part of government plans to tackle obesity levels in the UK.
Yahoo
37 minutes ago
- Yahoo
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, Wegovy. This decision was made less than two months after the companies had initially announced their collaboration. A healthcare professional holding a device with innovative technology developed by the medical technology company. According to Novo Nordisk, Hims & Hers failed to adhere to the law prohibiting mass sales of compounded drugs under the 'false guise of 'personalization'.' The company accused its partner of disseminating 'deceptive marketing' that risks patient safety and selling 'illegitimate, knockoff versions' of Wegovy. Novo Nordisk states that its investigation showed the active pharmaceutical ingredients (APIs) in these knockoff drugs, particularly 'semaglutide' from telehealth entities and compounding pharmacies, are manufactured by foreign suppliers in China and were often not inspected by the FDA. In response, Andrew Dudum, CEO of Hims & Hers, stated on X that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum alleged that Novo Nordisk's commercial team 'increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.' He asserted that Hims & Hers 'refuse[s] to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.' Novo Nordisk A/S (NYSE: NVO) is a Danish healthcare company operating globally. It develops, manufactures, and markets pharmaceutical products for the treatment of chronic diseases, primarily diabetes and obesity. Its well-known products include Ozempic, Wegovy, Rybelsus, and Norditropin. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
School sun safety lessons trialled to tackle skin cancer
Children as young as five are being taught how to check UV levels and apply sunscreen, as part of a new pilot aimed at reducing future skin cancer cases. The initiative, currently being trialled in primary schools across Kent, is planned to be introduced into Personal, Social, Health and Economic (PSHE) lessons nationwide from 2026. Melanoma, the most serious form of skin cancer, is linked to UV exposure - and experts say sunburn in childhood significantly increases the risk later in life. In 2021, around 18,300 people were diagnosed with melanoma in the UK, according to Cancer Research. That figure is projected to rise to 21,300 by 2026, the charity says. Michelle Baker, from the charity Melanoma Fund, which is behind the education project, said changing children's habits early is key. "People think melanoma is an older person's disease," she says, "but it's often seeded in childhood." She says the project aims to "grow skin cancer out of the next generation". Giving children a sense of control and responsibility for their sun protection is central to this. "We're saying this is your superpower," she adds. At Platt Primary school in Maidstone, pupils are learning to read UV indexes, apply sunscreen properly, and understand when they need protection. Headteacher Emma Smith said the pupils have been "really receptive". "If we educate them early, they're more likely to keep that knowledge as they get older - especially when social media starts to influence their choices." The childhood sun safety drive comes as Cancer Research UK says the rise in melanoma cases among adults is a particular cause for concern. A recent study from the charity found that cancer deaths cost the UK economy £10.3bn a year, more than any other health condition – underlining the importance of preventative measures. Consultant dermatologist Dr Katie Lacy says that educating children about how to look after their skin is key to reducing melanoma rates. Research shows that nine out of 10 cases are caused by UV exposure from the sun and sunbeds. Getting sunburnt regularly increases the chances of skin cancer. Dr Lacy stresses there is no such thing as a "safe tan", explaining that tanning is a response to skin damage. "Most melanomas don't come from existing moles - so if you notice something new, get it checked," she adds. She also highlights the growing role of AI in screening suspicious moles within the NHS - which could help streamline referrals to specialist services. The ABCDE checklist can help identify if a mole is abnormal: A - asymmetrical (does the mole have an uneven shape?) B - border (are the edges blurry or jagged?) C - colour (is it an uneven colour with different shades and tones?) D - diameter (is the mole bigger than your other ones?) E - evolving (is it changing, such as starting to itch, bleed or become crusty?) Source: Cancer Research UK For Kara Leece, diagnosed with melanoma at 29, the message is personal. "If I'd had that education at primary school, I think I could've prevented it," she told BBC News. "Now I have a scar that reminds me of what I've been through. When children ask about it, I tell them my story - because I don't want this to happen to anyone else." Try to keep children in the shade between 11am and 3pm, when the sun is at its strongest Kit them out with wide-brimmed hats, sunglasses and clothing to cover their skin. Sunscreen is also very important - apply it regularly and generously, and make sure it's at least SPF 30 and four or five stars Source: Cancer Research UK Melanoma skin cancer cases rising in UK Suncream should be everywhere - cancer sufferer Comic Ryan diagnosed with skin cancer for second time
